丽珠集团(000513) - 2025 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2025 was CNY 3,180,547,599.31, a decrease of 1.92% compared to CNY 3,242,814,513.73 in the same period last year[7] - Net profit attributable to shareholders increased by 4.75% to CNY 636,707,931.59 from CNY 607,823,809.46 year-on-year[7] - Basic and diluted earnings per share rose by 9.23% to CNY 0.71 from CNY 0.65 in the same period last year[7] - The company's operating revenue for the current period is RMB 3,180,547,599.31, a decrease of 1.92% from RMB 3,242,814,513.73 in the previous period[27] - The net profit attributable to shareholders of the parent company is RMB 636,707,931.59, up 4.76% from RMB 607,823,809.46 in the previous period[27] Cash Flow - The net cash flow from operating activities decreased by 21.59% to CNY 724,730,912.38 compared to CNY 924,248,920.31 in the previous year[7] - Total cash inflow from operating activities was RMB 3,427,996,327.57, down from RMB 3,508,763,815.99, reflecting a decline of 2.3%[29] - Cash outflow from operating activities increased to RMB 2,703,265,415.19, compared to RMB 2,584,514,895.68, marking an increase of 4.6%[29] - The net cash flow from investing activities was -RMB 221,749,900.37, an improvement from -RMB 457,336,601.18 in the previous period[29] - Cash inflow from investing activities totaled RMB 32,290,697.41, significantly higher than RMB 6,035,760.64 previously[29] - Cash outflow from investing activities decreased to RMB 254,040,597.78 from RMB 463,372,361.82, a reduction of 45.2%[29] - The net cash flow from financing activities was -RMB 487,915,315.07, an improvement from -RMB 654,613,688.15 in the previous period[29] - Total cash inflow from financing activities was RMB 630,140,000.00, down from RMB 721,939,862.90, a decrease of 12.7%[29] - The cash and cash equivalents at the end of the period amounted to RMB 10,821,444,006.06, slightly up from RMB 10,787,974,836.57[29] Assets and Liabilities - Total assets at the end of the reporting period were CNY 24,485,271,838.40, a slight increase of 0.12% from CNY 24,455,825,697.18 at the end of the previous year[8] - The company's equity attributable to shareholders increased by 2.19% to CNY 14,165,648,873.87 from CNY 13,862,334,189.33 at the end of the previous year[8] - The total liabilities decreased to RMB 9,109,970,328.17 from RMB 9,550,079,103.14, reflecting a reduction of approximately 4.62%[25] - Current assets totaled RMB 16,465,641,594.27, compared to RMB 16,419,980,644.30 at the beginning of the year[23] - Cash and cash equivalents stood at RMB 10,830,774,329.69, slightly up from RMB 10,827,146,984.92 at the start of the year[23] - The company's inventory decreased to RMB 1,900,256,033.70 from RMB 1,997,642,296.29 at the beginning of the year[23] - Long-term equity investments increased to RMB 1,061,082,396.62 from RMB 1,056,220,316.06[23] - The company has a total of 8,019,630,244.13 in non-current assets, slightly down from 8,035,845,052.88 at the beginning of the year[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 52,367, with 52,348 being A-share shareholders[16] - The company reported a total of 306,769,189 shares held by Hong Kong Central Clearing (Agent) Limited, representing 33.66% of the total shares[17] - Health元药业集团股份有限公司 holds 221,376,789 shares, accounting for 24.29% of the total shares[17] - The total number of shares repurchased by the company reached 9,425,955 A-shares, accounting for 1.03% of the total share capital, with a total expenditure of RMB 341,957,191.15[18] - The company also repurchased 7,245,300 H-shares, representing 0.80% of the total share capital, with a total expenditure of HKD 190,692,395.00[19] Expenses and Future Plans - Research and development expenses for the current period are RMB 216,076,782.61, down 9.25% from RMB 238,173,559.46 in the previous period[27] - The company reported a decrease in sales expenses to RMB 800,020,635.30 from RMB 876,113,247.33, a reduction of about 8.66%[27] - The company's financial expenses showed a slight improvement, with net financial income of RMB -56,040,353.34 compared to RMB -54,508,308.03 in the previous period[27] - The company plans to continue focusing on market expansion and new product development to drive future growth[27] Audit Information - The company did not undergo an audit for the first quarter report[30]